Caliway Biopharmaceuticals stock gets China trial clearance
Published on 11/20/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSChina trial advances development plans
- China's CDE authorized Caliway's CBL-0102 study of CBL-514 ahead of the company's anticipated timeline.
- Enrollment is expected to start in December 2026, with clinical results anticipated in the second quarter of 2027.
- The study is designed to assess pharmacokinetics, safety and tolerability in about 30 healthy Chinese participants.
Caliway Biopharmaceuticals announced on Thursday, November 19, that China's Center for Drug Evaluation has authorized its CBL-0102 clinical study of CBL-514 to proceed. The company said the clearance from the National Medical Products Administration came ahead of its anticipated timeline. PR Newswire published the company announcement on November 20.
China trial moves toward enrollment
CBL-0102 is expected to begin enrolling participants in December 2026 and is planned to be completed in the second quarter of 2027. Caliway expects clinical results shortly after completion and plans to use the findings for subsequent development and regulatory submissions.
The randomized, open-label, single-dose, parallel-design study is expected to enroll approximately 30 healthy participants at two sites in China. It will assess ethnicity sensitivity in a Chinese population, including the potential impact of ethnic factors on the pharmacokinetic profile, safety and tolerability of CBL-514 across different dose levels.
Potential role in Asian development
Caliway said results from Asian participants could support future pivotal Phase 3 studies and regulatory applications in China, while also serving as a reference for submissions in other Asian markets. The China program complements the company's development work in North America, Australia and Taiwan.
CBL-514 is an investigational small-molecule injection designed to induce adipocyte apoptosis and reduce localized subcutaneous fat. Caliway is also developing the candidate for moderate-to-severe cellulite and a separate formulation, CBL-514D, for Dercum's disease.
Caliway Biopharmaceuticals
- Company: Caliway Biopharmaceuticals Co., Ltd.
- ISIN: TW0006919004
- Ticker: 6919
- Home exchange: Taiwan Stock Exchange
- Clinical candidate: CBL-514
Taiwan's broader equity market is represented by the TAIEX.
